BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Ebola outbreak
Hantavirus
Trump administration impacts
Med-tech outlook 2026
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Wednesday, June 3, 2026
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Sep. 2, 2020
View Archived Issues
In T cells, exhaustion starts young
Read More
Antiviral protein produces flu mRNAs
Read More
Innovent opens phase I study in China with IBI-112 for autoimmune diseases
Read More
Additional interim results presented from proof-of-concept study of OTL-203 for MPS-I
Read More
Tohoku University divulges dioxolan derivatives for renal diseases
Read More
Novartis AG patents IKZF2 degradation inducers
Read More
Harvard College and Seoul National University disclose compounds for autoimmune disorders
Read More
PTC Therapeutics synthesizes new compounds for familial dysautonomia
Read More
Merck & Co. identifies new orexin receptor agonists
Read More
Preclinical and phase I data presented for GSK-3640254
Read More
Olfactory cells have unique response to flu virus
Read More
First clinical data for TAFIa inhibitor S-62798 presented
Read More
AM-535 demonstrates efficacy in model of diet-induced hyperammonemia
Read More
Elixirgen's COVID-19 vaccine candidate EXG-5003 set to enter phase I/II trials
Read More
Bristol-Myers Squibb reports phase I data for the antithrombotic milvexian
Read More
FDA approves Onureg for continued treatment of AML in first remission
Read More
Biotest completes phase III study of IgG Next Generation for primary immunodeficiency disease
Read More
Herantis' phase I/II study of CDNF for Parkinson's meets primary endpoint of safety and tolerability
Read More
Single domain antibody mimic receptors used to generate EGFR-HER2 bispecific CAR T cells
Read More
Atossa advances phase I study of AT-301 nasal spray for COVID-19
Read More
Arena begins phase II trial of etrasimod for moderate to severe alopecia areata
Read More
New phase III trial explores felbinac trometamol for postoperative pain in China
Read More
FDA approves Sogroya for adult growth hormone deficiency
Read More
FDA accepts INmune's IND for phase II trial of Quellor for immune-mediated complications of COVID-19
Read More
Poxel opens phase II trial of PXL-065 for noncirrhotic biopsy-proven NASH
Read More
Noxopharm cleared to begin phase I study of Veyonda for COVID-19
Read More
